Protalix BioTherapeutics, Inc. (FRA:PBDA)
Germany · Delayed Price · Currency is EUR 1.510
-0.040 (-2.58%)
At close: Nov 28, 2025
Protalix BioTherapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 61.84 | 53.4 | 65.49 | 47.64 | 38.35 | 62.9 | Upgrade | |
Revenue Growth (YoY) | 35.41% | -18.47% | 37.48% | 24.22% | -39.03% | 15.00% | Upgrade |
Cost of Revenue | 26.26 | 24.32 | 22.98 | 19.59 | 16.35 | 10.87 | Upgrade |
Gross Profit | 35.58 | 29.08 | 42.51 | 28.05 | 22 | 52.03 | Upgrade |
Selling, General & Admin | 11.16 | 12.19 | 14.96 | 11.71 | 12.73 | 11.15 | Upgrade |
Research & Development | 18.06 | 12.97 | 17.09 | 29.35 | 29.73 | 38.17 | Upgrade |
Operating Expenses | 29.21 | 25.16 | 32.05 | 41.06 | 42.46 | 49.32 | Upgrade |
Operating Income | 6.37 | 3.92 | 10.46 | -13.01 | -20.46 | 2.71 | Upgrade |
Interest Expense | -0.81 | -1.06 | -3.18 | -2.53 | -7.52 | -9.67 | Upgrade |
Interest & Investment Income | 0.93 | 1.3 | 1.29 | 1.15 | 0.4 | 0.44 | Upgrade |
EBT Excluding Unusual Items | 6.48 | 4.15 | 8.57 | -14.4 | -27.58 | -6.52 | Upgrade |
Pretax Income | 6.48 | 4.15 | 8.57 | -14.4 | -27.58 | -6.52 | Upgrade |
Income Tax Expense | 1.09 | 1.22 | 0.25 | 0.53 | - | - | Upgrade |
Earnings From Continuing Operations | 5.39 | 2.93 | 8.31 | -14.93 | -27.58 | -6.52 | Upgrade |
Net Income | 5.39 | 2.93 | 8.31 | -14.93 | -27.58 | -6.52 | Upgrade |
Net Income to Common | 5.39 | 2.93 | 8.31 | -14.93 | -27.58 | -6.52 | Upgrade |
Net Income Growth | - | -64.73% | - | - | - | - | Upgrade |
Shares Outstanding (Basic) | 76 | 73 | 68 | 48 | 44 | 29 | Upgrade |
Shares Outstanding (Diluted) | 85 | 81 | 82 | 48 | 44 | 29 | Upgrade |
Shares Change (YoY) | 15.89% | -1.66% | 70.04% | 9.81% | 51.43% | 96.44% | Upgrade |
EPS (Basic) | 0.07 | 0.04 | 0.12 | -0.31 | -0.62 | -0.22 | Upgrade |
EPS (Diluted) | 0.07 | 0.04 | 0.09 | -0.31 | -0.62 | -0.22 | Upgrade |
EPS Growth | - | -57.71% | - | - | - | - | Upgrade |
Free Cash Flow | -11.69 | 7.39 | -2.47 | -25.63 | -11.74 | -26.76 | Upgrade |
Free Cash Flow Per Share | -0.14 | 0.09 | -0.03 | -0.53 | -0.27 | -0.92 | Upgrade |
Gross Margin | 57.54% | 54.46% | 64.91% | 58.87% | 57.37% | 82.71% | Upgrade |
Operating Margin | 10.30% | 7.33% | 15.97% | -27.32% | -53.36% | 4.31% | Upgrade |
Profit Margin | 8.72% | 5.49% | 12.69% | -31.33% | -71.92% | -10.37% | Upgrade |
Free Cash Flow Margin | -18.91% | 13.84% | -3.77% | -53.80% | -30.62% | -42.55% | Upgrade |
EBITDA | 7.78 | 5.22 | 11.65 | -11.93 | -19.34 | 4.01 | Upgrade |
EBITDA Margin | 12.58% | 9.78% | 17.79% | -25.04% | -50.44% | 6.38% | Upgrade |
D&A For EBITDA | 1.41 | 1.3 | 1.19 | 1.09 | 1.12 | 1.3 | Upgrade |
EBIT | 6.37 | 3.92 | 10.46 | -13.01 | -20.46 | 2.71 | Upgrade |
EBIT Margin | 10.30% | 7.33% | 15.97% | -27.32% | -53.36% | 4.31% | Upgrade |
Effective Tax Rate | 16.81% | 29.42% | 2.96% | - | - | - | Upgrade |
Revenue as Reported | 61.84 | 53.4 | 65.49 | 47.64 | 38.35 | 62.9 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.